MCID: ALM001
MIFTS: 49

Al Amyloidosis malady

Categories: Rare diseases, Metabolic diseases, Nephrological diseases, Bone diseases, Immune diseases, Genetic diseases, Neuronal diseases, Cardiovascular diseases, Blood diseases

Aliases & Classifications for Al Amyloidosis

Aliases & Descriptions for Al Amyloidosis:

Name: Al Amyloidosis 50
Primary Systemic Amyloidosis 50 69
Primary Amyloidosis 50 69
Hereditary Amyloid Nephropathy Due to Lysozyme Variant 56
Familial Amyloid Nephropathy Due to Lysozyme Variant 56
Hereditary Renal Amyloidosis Due to Lysozyme Variant 56
Familial Renal Amyloidosis Due to Lysozyme Variant 56
Immunoglobulin Deposition Disease 69
Primary Systemic Al Amyloidosis 50
Amyloidosis Primary Systemic 50
Light Chain Amyloidosis 50
Primary Al Amyloidosis 50
Systemic Al Amyloidsis 50
Lysozyme Amyloidosis 56
Amyloidosis Primary 52
Alys Amyloidosis 56
Amyloidosis Al 50

Characteristics:

Orphanet epidemiological data:

56
alys amyloidosis
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide);

Classifications:



External Ids:

Orphanet 56 ORPHA93561
ICD10 via Orphanet 34 E85.0
ICD10 33 E85.9

Summaries for Al Amyloidosis

NIH Rare Diseases : 50 al amyloidosisis the most common form of amyloidosis, a group of disorders in which an abnormal protein called amyloid builds up in tissues and organs. the signs and symptoms of al amyloidosis vary among patients because the build up may occur in the tongue, intestines, muscles, joints, nerves, skin, ligaments, heart, liver, spleen, or kidneys. to diagnose al amyloidosis, healthcare professionals use blood or urine tests to identify signs of amyloid protein and a biopsy to confirm the diagnosis. treatment may include chemotherapy directed at the abnormal plasma cells, stem cell transplantation, or other treatments based on which symptoms have developed. last updated: 7/17/2015

MalaCards based summary : Al Amyloidosis, also known as primary systemic amyloidosis, is related to amyloidosis, primary localized cutaneous, 1 and amyloidosis, primary localized cutaneous, 2, and has symptoms including arthralgia, fatigue and dyspnea. An important gene associated with Al Amyloidosis is LYZ (Lysozyme), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Hematopoietic cell lineage. The drugs Dexamethasone and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and kidney.

Related Diseases for Al Amyloidosis

Diseases in the Amyloidosis family:

Amyloidosis, Hereditary, Transthyretin-Related Al Amyloidosis
Amyloidosis Aa Hereditary Amyloidosis
Primary Localized Amyloidosis Ah Amyloidosis

Diseases related to Al Amyloidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 83)
id Related Disease Score Top Affiliating Genes
1 amyloidosis, primary localized cutaneous, 1 12.2
2 amyloidosis, primary localized cutaneous, 2 12.2
3 primary cutaneous amyloidosis 11.8
4 multiple myeloma 11.4
5 light chain deposition disease 11.0
6 primary localized amyloidosis 10.9
7 amyloidosis 10.9
8 amyloidosis, hereditary, transthyretin-related 10.7
9 hepatitis 10.0
10 factor x deficiency 10.0
11 nephrotic syndrome 10.0
12 lymphoma 9.9
13 cardiomyopathy 9.9
14 carnitine-acylcarnitine translocase deficiency 9.9 IL3 MS4A1
15 cholestasis 9.8
16 basilar artery insufficiency 9.8 CALR IL3
17 monostotic fibrous dysplasia 9.8 LGALS3 MS4A1
18 mediastinitis 9.8
19 endotheliitis 9.8
20 neuropathy 9.8
21 macroglobulinemia 9.8
22 glomerulonephritis 9.8
23 leukemia 9.8
24 macroglossia 9.8
25 colitis 9.7
26 arthritis 9.7
27 rheumatoid arthritis 9.7
28 b-cell lymphomas 9.7
29 intrahepatic cholestasis 9.7
30 hepatitis c 9.7
31 gastroduodenitis 9.7
32 dilated cardiomyopathy 9.7
33 disseminated intravascular coagulation 9.7
34 plasmacytoma 9.7
35 polyneuropathy 9.7
36 pulmonary hypertension 9.5
37 poems syndrome 9.5
38 neuronitis 9.5
39 acute liver failure 9.5
40 suppurative cholangitis 9.5
41 adult t-cell leukemia 9.5
42 prostatitis 9.5
43 peritonitis 9.5
44 collagenous colitis 9.5
45 toxic megacolon 9.5
46 intestinal obstruction 9.5
47 atrial fibrillation 9.5
48 lung disease 9.5
49 factor v deficiency 9.5
50 diffuse large b-cell lymphoma 9.5

Graphical network of the top 20 diseases related to Al Amyloidosis:



Diseases related to Al Amyloidosis

Symptoms & Phenotypes for Al Amyloidosis

Human phenotypes related to Al Amyloidosis:

32 (show top 50) (show all 54)
id Description HPO Frequency HPO Source Accession
1 arthralgia 32 HP:0002829
2 fatigue 32 HP:0012378
3 dyspnea 32 HP:0002094
4 chronic constipation 32 HP:0012450
5 osteoarthritis 32 HP:0002758
6 hypertension 32 HP:0000822
7 macroglossia 32 HP:0000158
8 hepatomegaly 32 HP:0002240
9 malabsorption 32 HP:0002024
10 renal insufficiency 32 HP:0000083
11 proteinuria 32 HP:0000093
12 nephropathy 32 HP:0000112
13 hypertrophic cardiomyopathy 32 HP:0001639
14 hepatitis 32 HP:0012115
15 abnormal blistering of the skin 32 HP:0008066
16 congestive heart failure 32 HP:0001635
17 decreased antibody level in blood 32 HP:0004313
18 nephrotic syndrome 32 HP:0000100
19 goiter 32 HP:0000853
20 keratoconjunctivitis sicca 32 HP:0001097
21 hematuria 32 HP:0000790
22 xerostomia 32 HP:0000217
23 purpura 32 HP:0000979
24 gastrointestinal hemorrhage 32 HP:0002239
25 papule 32 HP:0200034
26 lymphadenopathy 32 HP:0002716
27 asplenia 32 HP:0001746
28 abnormality of bone marrow cell morphology 32 HP:0005561
29 edema of the lower limbs 32 HP:0010741
30 polyneuropathy 32 HP:0001271
31 abnormality of chromosome segregation 32 HP:0002916
32 upper airway obstruction 32 HP:0002781
33 pleural effusion 32 HP:0002202
34 orthostatic hypotension due to autonomic dysfunction 32 HP:0004926
35 adrenal insufficiency 32 HP:0000846
36 skin nodule 32 HP:0200036
37 elevated alkaline phosphatase 32 HP:0003155
38 aortic root dilatation 32 HP:0002616
39 autonomic dysregulation 32 HP:0002271
40 intermittent claudication 32 HP:0004417
41 abnormal ekg 32 HP:0003115
42 bradycardia 32 HP:0001662
43 autonomic bladder dysfunction 32 HP:0005341
44 pulmonary edema 32 HP:0100598
45 multiple myeloma 32 HP:0006775
46 arthropathy 32 HP:0003040
47 waldenstrom macroglobulinemia 32 HP:0005508
48 abnormality of the submandibular glands 32 HP:0010287
49 mechanical ileus 32 HP:0010676
50 plasmacytoma 32 HP:0011857

Drugs & Therapeutics for Al Amyloidosis

Drugs for Al Amyloidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
2
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
6
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
7
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
8
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
9
Morphine Approved, Investigational Phase 3 57-27-2 5288826
10
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
11
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
12
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Mechlorethamine Approved Phase 3,Phase 1,Phase 2 51-75-2 4033
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
17
Dalteparin Approved Phase 3 9041-08-1
18
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
19
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
20
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
21 Ixazomib Approved Phase 3,Phase 1 1072833-77-2
22
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
23
Glycine Approved, Nutraceutical, Vet_approved Phase 3,Phase 1 56-40-6 750
24 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
25 Analgesics Phase 3,Phase 2
26 Alkylating Agents Phase 3,Phase 2,Phase 1
27 glucocorticoids Phase 3,Phase 2,Phase 1
28
protease inhibitors Phase 3,Phase 2,Phase 1
29 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
30 Neurotransmitter Agents Phase 3,Phase 1
31 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
32 Hormone Antagonists Phase 3,Phase 2,Phase 1
33 Dexamethasone 21-phosphate Phase 3,Phase 2,Phase 1
34 Anesthetics Phase 3
35 Hormones Phase 3,Phase 2,Phase 1
36 Anesthetics, Dissociative Phase 3
37 Anesthetics, General Phase 3
38 Anesthetics, Intravenous Phase 3
39 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
40 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
42 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
44 Excitatory Amino Acid Antagonists Phase 3
45 Excitatory Amino Acids Phase 3
46 Anti-Infective Agents Phase 3,Phase 2,Phase 1
47 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
48 Antiemetics Phase 3,Phase 2,Phase 1
49 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
50 Antirheumatic Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 155)
id Name Status NCT ID Phase
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
2 Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis Completed NCT01998503 Phase 3
3 Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis Completed NCT00344526 Phase 3
4 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed NCT00477971 Phase 3
5 A Trial for Systemic Light-chain (AL) Amyloidosis Completed NCT01277016 Phase 3
6 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed NCT01078454 Phase 3
7 Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed NCT00004165 Phase 3
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
13 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
14 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
15 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
16 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
17 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
18 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
19 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
20 Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis Recruiting NCT01659658 Phase 3
21 The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis Active, not recruiting NCT02312206 Phase 3
22 Trial of HDM/SCT Versus HDM + Bortezomib/SCT in AL Amyloidosis Suspended NCT02489500 Phase 3
23 S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis Unknown status NCT00064337 Phase 2
24 Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) Unknown status NCT00981708 Phase 1, Phase 2
25 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2
26 Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction Completed NCT00547365 Phase 1, Phase 2
27 A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis Completed NCT00883623 Phase 2
28 Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis Completed NCT00607581 Phase 2
29 S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis Completed NCT00002849 Phase 2
30 CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed NCT00091260 Phase 2
31 Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed NCT00679367 Phase 2
32 Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed NCT00790647 Phase 2
33 Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis Completed NCT00166413 Phase 2
34 Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis Completed NCT01072773 Phase 2
35 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis Completed NCT00003853 Phase 2
36 Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis Completed NCT00089167 Phase 2
37 Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed NCT00564889 Phase 2
38 High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis Completed NCT00003353 Phase 2
39 Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed Completed NCT01194791 Phase 2
40 Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis Completed NCT01527032 Phase 2
41 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis Completed NCT00007995 Phase 2
42 Autologous Stem Cell Rescue for Primary Amyloidosis Completed NCT00186407 Phase 2
43 Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis Completed NCT00458822 Phase 2
44 Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis Completed NCT00017680 Phase 2
45 High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis Completed NCT00002810 Phase 2
46 Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden Completed NCT00651937 Phase 2
47 Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis Completed NCT00298766 Phase 1, Phase 2
48 Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis Completed NCT00621400 Phase 1, Phase 2
49 Safety and Effect of Doxycycline in Patients With Amyloidosis Completed NCT01677286 Phase 2
50 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2

Search NIH Clinical Center for Al Amyloidosis

Genetic Tests for Al Amyloidosis

Anatomical Context for Al Amyloidosis

MalaCards organs/tissues related to Al Amyloidosis:

39
Heart, Liver, Kidney, Skin, Bone, Testes, Spleen

Publications for Al Amyloidosis

Articles related to Al Amyloidosis:

(show top 50) (show all 539)
id Title Authors Year
1
Lung adenocarcinoma expressing receptor for advanced glycation end-products with primary systemic AL amyloidosis: a case report and literature review. ( 28056871 )
2017
2
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. ( 27729322 )
2017
3
Fatal recurrent dermatoneuro syndrome associated with systemic AL amyloidosis. ( 26754417 )
2016
4
Multiple qualitative and quantitative methods for free light chain analysis are necessary as first line tests for AL amyloidosis. ( 26760309 )
2016
5
A patient with AL amyloidosis with negative free light chain results. ( 26677890 )
2016
6
Isaacs' syndrome with overlapping myopathy as the first manifestation of AL amyloidosis. ( 27699467 )
2016
7
Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. ( 27288311 )
2016
8
Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. ( 26658109 )
2016
9
Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units. ( 27292694 )
2016
10
2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis (a8 ). ( 27494229 )
2016
11
Rare and unusual clinicopathologic presentation of renal AL amyloidosis. ( 27186381 )
2016
12
Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis. ( 26812792 )
2016
13
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. ( 27904139 )
2016
14
Systemic AL amyloidosis associated with WaldenstrAPm macroglobulinemia: an unusual presenting complication. ( 27127826 )
2016
15
Penile ulcers complicating systemic AL amyloidosis: a case report. ( 27187183 )
2016
16
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. ( 26943606 )
2016
17
Editor's choice: Is there still a place for autologous stem cell transplantation in systemic AL amyloidosis with severe renal disease? ( 26908764 )
2016
18
Mediastinal nodular AL-amyloidosis with progressive calcification. ( 27521579 )
2016
19
A Liver transplantation followed by autologous stem cell transplantation for acute liver failure caused by AL amyloidosis. Case report and review of the literature. ( 27236160 )
2016
20
Defining ultrahigh-risk AL amyloidosis with VWF. ( 27445410 )
2016
21
Monoclonal IgM-related AL amyloidosis. ( 27825470 )
2016
22
Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement. ( 26862817 )
2016
23
Successful Treatment of Hepatitis C Infection While Receiving Concurrent Chemotherapy for AL Amyloidosis. ( 26869507 )
2016
24
Clinical benefits of bortezomib-containing regimens for newly diagnosed AL amyloidosis with severe cardiac impairment. ( 27599413 )
2016
25
Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients (.) ( 27460276 )
2016
26
Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. ( 27356490 )
2016
27
Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. ( 27677679 )
2016
28
Primary AL amyloidosis presenting with systemic lymphadenopathy with calcification. ( 27631125 )
2016
29
Bendamustine-Induced Nephrogenic Diabetes Insipidus inA aA Patient With AL Amyloidosis. ( 27780577 )
2016
30
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. ( 27211265 )
2016
31
Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. ( 26773409 )
2016
32
Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study. ( 27832515 )
2016
33
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. ( 27257181 )
2016
34
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. ( 27416985 )
2016
35
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody. ( 27648922 )
2016
36
Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. ( 27183092 )
2016
37
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. ( 27166361 )
2016
38
Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. ( 27647123 )
2016
39
Non-Hodgkin's lymphoma causing light-chain (AL) amyloidosis. ( 26961452 )
2016
40
Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins. ( 27412900 )
2016
41
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009. ( 27694943 )
2016
42
Ascites in the course of plasma cell myeloma complicated by AL-amyloidosis. ( 27531413 )
2016
43
Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. ( 27381904 )
2016
44
New and developing therapies for AL amyloidosis. ( 28002971 )
2016
45
Bone marrow amyloid spherulites in a case of AL amyloidosis. ( 27067483 )
2016
46
Primary AL amyloidosis presenting as lower motor neuron disease. ( 27084240 )
2016
47
99mTc-DPD-scintigraphy with intense uptake in fat tissue caused by AL-amyloidosis. ( 27351183 )
2016
48
Immunomodulatory drugs in AL amyloidosis. ( 26806146 )
2016
49
Aggregation of Full Length Immunoglobulin Light Chains from AL Amyloidosis Patients Is Remodeled by Epigallocatechin-3-gallate. ( 28031465 )
2016
50
Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis. ( 27682970 )
2016

Variations for Al Amyloidosis

Expression for Al Amyloidosis

Search GEO for disease gene expression data for Al Amyloidosis.

Pathways for Al Amyloidosis

Pathways related to Al Amyloidosis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.02 IL3 MS4A1
2 10.61 IL3 MS4A1

GO Terms for Al Amyloidosis

Cellular components related to Al Amyloidosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.46 CALR LGALS3 LYZ MS4A1
2 extracellular region GO:0005576 9.26 CALR IL3 LGALS3 LYZ
3 extracellular space GO:0005615 9.02 CALR IL3 LGALS3 LYZ MS4A1

Biological processes related to Al Amyloidosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA replication GO:0045740 8.62 CALR IL3

Molecular functions related to Al Amyloidosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 8.62 CALR LGALS3

Sources for Al Amyloidosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....